ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Study of the Scandinavian Total Ankle Replacement (STAR) for the Treatment of Bilateral Degenerative Ankle Disease

This study has been completed.

Sponsored by: Link America, Inc.
Information provided by: Link America, Inc.
ClinicalTrials.gov Identifier: NCT00586781
  Purpose

The purpose of this study is to evaluate the safety of the S.T.A.R. device for patients with bilateral disease.


Condition Intervention Phase
Osteoarthritis
Post-Traumatic Arthritis
Rheumatoid Arthritis
Device: Scandinavian Total Ankle Replacement (STAR)
Phase III

MedlinePlus related topics:   Osteoarthritis    Rheumatoid Arthritis   

ChemIDplus related topics:   Chromium    Cobalt   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety Study
Official Title:   Investigational Device Exemption for the Scandinavian Total Ankle Replacement (STAR) - Bilateral Arm

Further study details as provided by Link America, Inc.:

Primary Outcome Measures:
  • Safety endpoints to be measured are: • Device failure or device removal/revision • Radiographically confirmed loosening and migration • Complications [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]

Enrollment:   21
Study Start Date:   September 2001
Primary Completion Date:   December 2006 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
3: Experimental
The S.T.A.R. ankle system is the study device. The device has three parts: two metal bearing surfaces (cobalt-chromium alloy) plates with bars that fit into the bone and one plastic (polyethylene) spacer that moves between the metal plates like a ball bearing. The materials in the S.T.A.R. device are the same materials used in total hip and knee implants. Both ankles of every subject will be treated with the STAR ankle.
Device: Scandinavian Total Ankle Replacement (STAR)
The device has three parts: two metal bearing surfaces (cobalt-chromium alloy) plates with bars that fit into the bone and one plastic (polyethylene) spacer that moves between the metal plates like a ball bearing. The materials in the S.T.A.R. device are the same materials used in total hip and knee implants.

Detailed Description:

The specific objectives are to show that the safety data of the S.T.A.R. ankle arthroplasty is similar for treatment of single ankle disease (as defined in the pivotal study) and bilateral ankle disease. The bilateral disease may be identified at the time of enrollment or may have progressed after enrollment and treatment of the first ankle in the pivotal study.

  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Criteria

Inclusion Criteria:

  • Moderate or severe pain, loss of mobility and function of the ankle
  • Primary arthrosis, post traumatic arthrosis or rheumatoid arthrosis
  • At least six months of conservative treatment for severe ankle conditions
  • Bilateral ankle disease that have not been enrolled in the pivotal study or single ankle disease and enrolled in the pivotal study but have subsequently developed ankle disease in the contralateral ankle and require surgical intervention
  • Willing and able to give informed consent

Exclusion Criteria:

  • Patients who have not reached skeletal maturity
  • Active or prior deep infection in the ankle joint or adjacent bones
  • Prior arthrodesis at the involved site
  • History of prior mental illness or patient demonstrates that their mental capacity may interfere with their ability to follow the study protocol
  • Obesity (weight greater than 250 lbs)
  • History of current or prior drug abuse or alcoholism
  • Any physical condition precluding major surgery
  • Prior surgery and/or injury that has adversely affected the ankle bone stock
  • Severe osteoporotic or osteopenic condition or other conditions that may lead to inadequate implant fixation in the bone
  • Insufficient ligament support
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00586781

Locations
United States, Florida
Mayo Clinic    
      Jacksonville, Florida, United States, 32224
United States, Iowa
University of Iowa    
      Iowa City, Iowa, United States, 52242
United States, Kansas
Kansas University Medical Center    
      Kansas City, Kansas, United States, 66160
United States, North Carolina
Duke University Medical Center    
      Durham, North Carolina, United States, 27710
United States, Texas
Orthopedic Associates of Dallas    
      Dallas, Texas, United States, 75246

Sponsors and Collaborators
Link America, Inc.

Investigators
Principal Investigator:     Roger A Mann, MD     Roger A Mann, Inc    
Principal Investigator:     Michael J Coughlin, MD     Foot and Ankle    
  More Information


Responsible Party:   Link America, Inc ( Andrew Greenberg, President )
Study ID Numbers:   Link-3
First Received:   December 21, 2007
Last Updated:   December 21, 2007
ClinicalTrials.gov Identifier:   NCT00586781
Health Authority:   United States: Food and Drug Administration

Keywords provided by Link America, Inc.:
ankle replacement  
end-stage arthritis of the ankle  
degenerative ankle disease  

Study placed in the following topic categories:
Autoimmune Diseases
Chromium
Musculoskeletal Diseases
Osteoarthritis
Cobalt
Joint Diseases
Arthritis
Connective Tissue Diseases
Arthritis, Rheumatoid
Rheumatic Diseases

Additional relevant MeSH terms:
Immune System Diseases

ClinicalTrials.gov processed this record on October 03, 2008




Links to all studies - primarily for crawlers